• Sign the informed consent form voluntarily and follow the protocol requirements;

• Gender is not limited;

• Age ≥18 years old and ≤75 years old;

• Expected survival time ≥3 months;

• Patients with recurrent or metastatic head and neck squamous cell carcinoma;

• Consent to provide tumor tissue samples or fresh tissue samples archived from the primary or metastatic lesions within 2 years;

• At least one measurable lesion meeting the RECIST v1.1 definition was required;

• Physical status score: ECOG ≤1;

• The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

⁃ No blood transfusion or colony-stimulating factor was allowed within 14 days before the first use of the study drug, and the organ function level must meet the requirements;

⁃ Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

⁃ Urinary protein ≤1+ or ≤1000mg/24h;

⁃ Fertile female subjects, or male subjects with fertile partners, must use highly effective contraception from 7 days before the first dose until 24 weeks after the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.